Profound Medical Corp PROF

$5.86 +0.08 (1.38%)

Valuation

Market cap
214,083,000
Revenue TTM
$16,100,000
Net income TTM
$-42,570,000
PE ratio
0.00
Forward PE
—
Profit margin
-264.41%
Debt to equity
0.09

Trading

Volume
67,400
Avg volume
205,156
Day's range
$5.80 – $5.94
Shares out
36,533,000
Stochastic %K
33%
Beta
0.72
Analysts
Strong Sell
Price target
$11.12

Price

Company profile

Profound Medical Corp. operates as a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapeutic systems for the image guided ablation of diseased tissue. The company's lead product TULSA-PRO system combines magnetic resonance imaging (MRI), robotically driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate...

Show more

Profound Medical Corp. operates as a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapeutic systems for the image guided ablation of diseased tissue. The company's lead product TULSA-PRO system combines magnetic resonance imaging (MRI), robotically driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. It also provides Sonalleve, which combines real-time MRI and thermometry for the treatment of uterine fibroids, adenomyotic tissue, palliative pain treatment of bone metastases, osteoid osteoma, and management of benign tumors. It operates in Canada, Germany, the United States, China, and Finland. Profound Medical Corp. is headquartered in Mississauga, Canada.

Industry
Medical Devices
Sector
Healthcare
Phone
647 476 1350
Website
https://www.profoundmedical.com
Address
2400 Skymark Avenue, Unit 6, Mississauga, Canada

Latest news

No headlines yet.